Çàðåãèñòðèðîâàòüñÿ

Ïîõîæèå òåìû

  1. èììóíèòåò
    îò Amon â ðàçäåëå Àëëåðãèÿ, èììóíîëîãèÿ
    Îòâåòîâ: 0
    : 16.03.2006, 11:02
  2. èììóíèòåò
    îò kniaginia â ðàçäåëå Ãèíåêîëîã-àêóøåð, áåðåìåííîñòü, ðîäû
    Îòâåòîâ: 10
    : 01.06.2005, 20:05
  3. Èììóíèòåò
    îò Ñàìà ñåáå õîçÿéêà â ðàçäåëå Ãèíåêîëîã-àêóøåð, áåðåìåííîñòü, ðîäû
    Îòâåòîâ: 17
    : 25.05.2005, 14:31
  4. èììóíèòåò
    îò shcnik â ðàçäåëå Ýíäîêðèíîëîã
    Îòâåòîâ: 4
    : 01.09.2004, 19:30
  5. Èììóíèòåò
    îò Oleg â ðàçäåëå Òåðàïåâò
    Îòâåòîâ: 1
    : 08.08.2003, 17:53
  1. Diamond_Virus
    #46
    ×èòàòåëü Íåäóã.Ðó
    ß íå çíàëà ãäå çàäàòü äàííûé âîïðîñ.

    Ïîäñêàæèòå ïîæàëóéñòà êàêèìè ñðåäñòâàìè ìîæíî ïîâûñèòü ñâîé èììóíèòåò?

  2. Alexsandr
    #47
    ×èòàòåëü Íåäóã.Ðó
    Èâàí, à íåëüçÿ ëè ïîòî÷íåå ïðî èììóíîäåôèöèòû, èììóíîìîäóëÿòîðû è ò.ï.? ×òî çà òðàíçèòîðíûå èììöóíîäåôèöèòû? Ýòî ÿ íå ðàäè ïîëèâàíèÿ ãðÿçüþ èììóíîìîäóëÿòîðîâ, ïðîñòî ïîíÿòü íå ìîãó

  3. svc
    #48
    ×èòàòåëü Íåäóã.Ðó
    Ïðèñîåäèíÿþñü ê ïðîñüáå Àëåêñàíäðà!

    Èâàí, åñëè ìîæíî, ÷óòü ïîäðîáíåå îá èììóíîìîäóëÿòîðàõ, äîêàçàòåëüíîé áàçå äëÿ íèõ è ïðàêòè÷åñêèå ñîîáðàæåíèÿ.

  4. MAXFISH
    #49
    ×èòàòåëü Íåäóã.Ðó
    Î ìåõàíèçìàõ âîçíèêíîâåíèÿ è êëàññèôèêàöèÿõ òðàíçèòîðíûõ èììóíîäåôèöèòîâ íóæíî ñïðàøèâàòü âðà÷åé àëëåðãîëîãîâ-èììóíîëîãîâ. Òðàíçèòîðíûå èììóíîäåôèòû èëè ïðîõîäÿùèå õàðàêòåðèçóþòñÿ ñåçîííîñòüþ òå÷åíèÿ. Åñëè ýòî êàñàåòñÿ ãåðïåñà, òî âîçìîæíû ÷àñòûå ðåöèäèâû â ìåæñåçîíüå: îñåíü, âåñíà. Ïî äàííûì ó÷¸íûõ èç ÃÍÖ ÐÔ Èíñòèòóòà èììóíîëîãèè ÔÌÁÀ Ðîññèè ó ïàöèåíòîâ "èììóíîëîãè÷åñêè çäîðîâûõ" â îñòàëüíûå âðåìåíà ãîäà, â ìåæñåçîíüå âîçíèêàþò îïðåäåë¸ííûå íàðóøåíèÿ ðàáîòû èììóííîé ñèñòåìû, ÷òî ïðèâîäèò ê ðåöèäèâàì.

    ×òî êàñàåòñÿ äîêàçàòåëüíîé áàçû: áàçà ñóùåñòâóåò. Óðîâåíü äîêàçàòåëüíîñòè íèçêèé ïî ìèðîâûì ñòàíäàðòàì.

  5. Tatiyana
    #50
    ×èòàòåëü Íåäóã.Ðó
    À âîò ìíåíèå èììóíîëîãà-àëëåðãîëîãà"

    "...ðåáåíîê ìîæåò áîëåòü ÎÐÇ õîòü 10-15 ðàç â ãîä, íî åñëè îí êàæäûé ðàç ñàì è áåç îñîáûõ óñèëèé âðà÷åé âûçäîðàâëèâàåò, òî ó òàêîãî ðåáåíêà íåò ïðîáëåì ñ èììóíèòåòîì..."



    "Ìû ãîâîðèì î ÷àñòî áîëåþùèõ äåòÿõ. Êàêîé êðèòåðèé, ÷òî îíè áîëåþò ÷àñòî? Åñëè ðåáåíîê áîëååò ÎÐÂÈ 4-6 ðàç â ãîä, ýòî ìíîãî? Ìíå êàæåòñÿ, â òàêîì ñëó÷àå íàäî ðàçáèðàòüñÿ, ÷òî ñêðûâàåòñÿ ïîä ýòèì äèàãíîçîì, à ÎÐÂÈ ëè ýòî. Íàïðèìåð, èç ìîåãî îïûòà ðàáîòû ñ âçðîñëûìè ïàöèåíòàìè - ÷àñòî ïîä òàêèì äèàãíîçîì ñêðûâàåòñÿ àëëåðãè÷åñêàÿ ïàòîëîãèÿ è ïðè îáñëåäîâàíèè âûÿâëÿåò àëëåðãè÷åñêèé ðèíèò è/èëè áðîíõèàëüíàÿ àñòìà, ïðè÷åì ñ òèïè÷íîé êëèíè÷åñêîé êàðòèíîé. Òîãäà òàêèõ äåòåé äåéñòâèòåëüíî íàäî íàïðàâëÿòü ê àëëåðãîëîãó-èììóíîëîãó, íî èìåííî ñ ïîäîçðåíèåì íà àëëåðãè÷åñêóþ ïàòîëîãèþ, âîçìîæíû è äðóãèå âàðèàíòû, òóò óæ çàäà÷à ïåäèàòðà ðàçáèðàòüñÿ.



    Ìíå ïðîñòî õîòåëîñü âûñêàçàòü ñâîþ ëè÷íóþ òî÷êó çðåíèÿ. ß ïÿòü ëåò (îäèíàòóðà+àñïèðàíòóðà) ïðîðàáîòàëà â ýòîé ñôåðå è ñ÷èòàþ, ÷òî ó íàñ ñëèøêîì ïðåóâåëè÷èâàåòñÿ çíà÷èìîñòü êîíñóëüòàöèè ó èììóíîëîãà, ýòîò âðà÷ ðàñöåíèâàåòñÿ êàê ïîñëåäíÿÿ íàäåæäà ïàöèåíòà. Ìíîãèå âçðîñëûå ïàöèåíòû, íàïðàâëåííûå íà êîíñóëüòàöèþ àëëåðãîëîãà-èììóíîëîãà ïî ïîâîäó «âòîðè÷íîãî èììóíîäåôèöèòà» íóæäàþòñÿ ñêîðåå â êîíñóëüòàöèè ïñèõèàòðà, â âèäó íàëè÷èÿ ïîãðàíè÷íîé ïñèõè÷åñêîé ïàòîëîãèè èëè äàæå ýíäîãåííîãî çàáîëåâàíèÿ. Íåîïðàâäàííî ÷àñòî íàçíà÷àåòñÿ èññëåäîâàíèå èììóííîãî ñòàòóñà. Òîãäà êàê èññëåäîâàíèå òåõ èëè èíûõ ïîêàçàòåëåé èììóííîãî ñòàòóñà (èìåþ â âèäó îïðåäåëåíèå ñóáïîïóëÿöèé ëèìôîöèòîâ, ôàãîöèòîçà, óðîâíÿ ñûâîðîòî÷íûõ èììóíîãëîáóëèíîâ è íåêîòîðûå äðóãèå ïîêàçàòåëè) èìååò çíà÷åíèå äëÿ óñòàíîâêè äèàãíîçà è/èëè îïðåäåëåíèÿ ïðîãíîçà ïðåèìóùåñòâåííî â 3 ñèòóàöèÿõ - ïîäîçðåíèå íà ïåðâè÷íûé èììóíîäåôèöèò, ÂÈ×-èíôåêöèÿ íó è îíêîãåìàòîëîãèÿ.



    ×òî êàñàåòñÿ èììóíîìîäóëèðóþùèõ ïðåïàðàòîâ, òî, ê ñîæàëåíèþ, íàñêîëüêî ÿ ïîíèìàþ, ïîëíîöåííûõ äîêàçàòåëüíûõ ìóëüòèöåíòðîâûõ èññëåäîâàíèé ïî åäèíîìó ïðîòîêîëó äëÿ áîëüøèíñòâà øèðîêî ðåêëàìèðóåìûõ ñåé÷àñ ïðåïàðàòîâ íå áûëî. Ïðîáëåìà ìíå åùå âèäèòñÿ â òîì, ÷òî êîãäà ÷èòàåøü àííîòàöèþ ê ïðåïàðàòó èëè ñòàòüþ, òî âñå êàæåòñÿ çàìå÷àòåëüíûì, à âîò â ðåàëüíîñòè âñå íåìíîãî íå òàê. Âåäü åñëè, ê ïðèìåðó, ÿ íàçíà÷àþ ïàöèåíòó ñ áðîíõèàëüíîé àñòìîé èíãàëÿöèîííûå ÃÊÑ, òî â áîëüøèíñòâå ñëó÷àåâ ïîëó÷ó ïîëîæèòåëüíûé îòâåò, äðóãîé âîïðîñ, ÷òî ìîæåò áûòü íóæíà áóäåò êîððåêöèÿ äîçû è ò.ï., òîæå ìû ìîæåì ñêàçàòü îá àäåêâàòíîé àíòèáàêòåðèàëüíîé òåðàïèè, àíòèãèïåðòåíçèâíûõ ïðåïàðàòàõ è äð. À âîò ñ èììóíîìîäóëÿòîðàìè òàê íå ïîëó÷àåòñÿ. ÈÌÕÎ, â ïðèìåíåíèè èììóíîìîäóëèðóþùèõ ïðåïàðàòîâ áîëüøå âîïðîñîâ, ÷åì îòâåòîâ, ÷òîáû âîò òàê ïðîñòî èñïîëüçîâàòü èõ ó ÷àñòî áîëåþùèõ äåòåé.



    À îòäåëüíîé ñïåöèàëüíîñòè èììóíîëîãèÿ íåò, åñòü îäíà ñïåöèàëüíîñòü 14.00.36 «Àëëåðãîëîãèÿ è èììóíîëîãèÿ», íî åñòü îñîáåííîñòü, ÷òî ñïåöèàëüíîñòü îäíà è äëÿ âðà÷à ëå÷åáíèêà, îêîí÷èâøåãî îðäèíàòóðó, è äëÿ âðà÷à-èññëåäîâàòåëÿ èëè áèîëîãà. È íå ðåäêîñòü, êîãäà â êà÷åñòâå êîíñóëüòàíòà âûñòóïàåò èìåííî âðà÷-èññëåäîâàòåëü, îñîáåííî â êîììåð÷åñêèõ ñòðóêòóðàõ. "

  6. Âëàäèìèð_Â×
    #51
    ×èòàòåëü Íåäóã.Ðó
    Ðå÷ü âðîäå áû øëà î âçðîñëîé æåíùèíå. Ïðè÷¸ì çäåñü äåòè? Íå íóæíî ìåøàòü â îäíó êó÷ó ëþäåé è êîíåé.

  7. êàòàðèíà
    #52
    ×èòàòåëü Íåäóã.Ðó
    À âîò ìíåíèå èììóíîëîãà-àëëåðãîëîãà"

    "...ðåáåíîê ìîæåò áîëåòü ÎÐÇ õîòü 10-15 ðàç â ãîä, íî åñëè îí êàæäûé ðàç ñàì è áåç îñîáûõ óñèëèé âðà÷åé âûçäîðàâëèâàåò, òî ó òàêîãî ðåáåíêà íåò ïðîáëåì ñ èììóíèòåòîì..."

    Ñìåÿòüñÿ èëè ïëàêàòü?

  8. sweet_fase
    #53
    ×èòàòåëü Íåäóã.Ðó
    Êëèíè÷åñêèå ïîäõîäû â ýòîì ñëó÷àå îòëè÷àòüñÿ íå áóäóò. Ïðîñòî ýòà öèòàòà áûëà èìåííî î äåòÿõ.



    "... Êñòàòè, ê èììóíîëîãó ïîñûëàþò íå òîëüêî äåòåé, íî è âçðîñëûõ. À âðà÷ó àëëåðãîëîãó-èììóíîëîãó ïîòîì ïðèõîäèòñÿ óáåæäàòü ïàöèåíòà, ÷òî ó íåãî âñå íîðìàëüíî ñ èììóíèòåòîì è åìó íå íóæíî ñäàâàòü àíàëèç íà èììóííûé ñòàòóñ, à ñëîæíåå âñåãî, êîãäà ïðèõîäèò ïàöèåíò óæå ñî ñäåëàííûì èììóííûì ñòàòóñîì, à òàì êàêèå-òî îòêëîíåíèÿ îò "íîðìû", âîò òóò ïðèõîäèòñÿ òóãî, ò.ê. ñåé÷àñ âñåì èçâåñòíî, ÷òî âñå áîëåçíè îò èììóíèòåòà."

  9. TatyanaCH
    #54
    ×èòàòåëü Íåäóã.Ðó
    Íó, íó. Âñû ¸ùå ñêàæèòå, ÷òî ïåäèàòðû íå íóæíû. Âåçäå îäèíàêîâûå êëèíè÷åñêèå ïîäõîäû.

    Èíòåðåñíî, âñå ëè ðóññêèå ïåðåáðàâøèåñÿ â USA îáëàäàþò òàêèì èíòåëëåêòîì èëè îò ÷åëîâåêà çàâèñèò?

  10. Arina
    #55
    ×èòàòåëü Íåäóã.Ðó
    Ïðîñòèòå, Èâàí, ÿ íå ñîâñåì ïîíÿëà, ÷åé èíòåëëåêò Âû õîòåëè áû îáñóäèòü?

    Ïåäèàòðû î÷åíü íóæíû, íî íå òå, êîòîðûå íàçíà÷àþò äåòÿì èììóíoìîäóëÿòîðû ïðè ïðîñòóäàõ.

  11. Àëåíüêà
    #56
    ×èòàòåëü Íåäóã.Ðó
    Ñìåÿòüñÿ èëè ïëàêàòü?

    Ó÷èòüñÿ.

    ------------------

    Evaluation of Suspected Immunodeficiency



    Children with recurrent infections are among the most frequent types of patients seen by primary care physicians. The number of pediatric patients suspected of having primary or secondary immunodeficiency far exceeds the actual number of cases despite the emergence of the human immunodeficiency virus (HIV) epidemic. Most patients with recurrent infections do not have an identifiable immunodeficiency disorder. A major reason for the apparent high rate of recurrent infections is excessive exposure of infants or children to infectious agents in out-of-home child care and other group settings. In addition, excessive use of antibiotics by physicians has masked the classic presentation of many of the primary immunodeficiency diseases.

    Primary care physicians must have a high index of suspicion if defects of the immune system are to be diagnosed early enough that appropriate treatment can be instituted before there is irreversible damage. This problem is made more difficult because none of these defects are screened for currently in the perinatal period or later in childhood, and there is widespread use of antibiotics for respiratory infections, which can mask genetic defects in the immune system. Evaluation of immune function should be initiated for children with clinical manifestations of a specific immune disorder or with unusual, chronic, or recurrent infections such as (1) two or more systemic or serious bacterial infections (e.g., sepsis, osteomyelitis, or meningitis); (2) three or more serious respiratory or documented bacterial soft tissue infections (e.g., cellulitis, draining otitis media, or lymphadenitis) within 1 yr; (3) infections occurring at unusual sites (e.g., liver or brain abscess); (4) infections with unusual pathogens (e.g., Aspergillus, Serratia marcescens, Nocardia, or Burkholderia cepacia); and (5) infections with common childhood pathogens but of unusual severity.

    The screening tests selected for immunologic evaluation should be broadly informative, reliable, and cost effective. Familiarity with certain clinical guidelines aids in the initial selection of tests. Patients with deficiencies of antibodies, phagocytic cells, or complement have recurrent infections with encapsulated bacteria. Thus, patients with only repeated viral infections (with the exception of persistent enterovirus infections) are not as likely to have any of these disorders. Children with defects in antibody production, phagocytic cells, or complement proteins may grow and develop normally despite their recurrent infections unless they develop bronchiectasis from repeated lower respiratory tract bacterial infections or have persistent enteroviral infections of the central nervous system. By contrast, patients with deficiencies in T-cell function usually develop opportunistic infections early in life and fail to thrive.

    ----------

    È ò.ä.

  12. Ìèêóëè÷
    #57
    ×èòàòåëü Íåäóã.Ðó
    Óâàæàåìûé Àíòîí Âëàäèìèðîâè÷!

    Êàê Âû ïîíèìàåòå, â äàííîì ñëó÷àå, ýòî áûëè íå ÁÀÄû. Äëÿ íèõ â êëèíèêó êëàñòü íåò íåîáõîäèìîñòè. È åñëè áû Ìàêñèìîâ ñàì íåñêîëüêî ëåò íå áûë ñâÿçàí ñ äàííîé ìåòîäèêîé (äàæå ñàì ëå÷èëñÿ), íå áûë ðóêîâîäèòåëåì íåñêîëüêèõ äèññåðòàöèé, â òîì ÷èñëå äîêòîðñêèõ, ïîëàãàþ, ñóåòèòñÿ, ïðèâîçèòü èçäàëåêà ñâîþ ìàìó, îí íå ñòàë áû.

    Äàëåå óãëóáëÿòüñÿ íå áóäó, à òî îïÿòü âûçîâó ñòðàøíûé ãíåâ ñèëüíûõ ôîðóìà ñåãî.

    Íî åù¸ ðàç ïðåäëàãàþ ñâÿçàòü Âàñ ñ Ìàêñèìîâûì, äàæå ïîïûòàþñü ïîëó÷èòü åãî ñîãëàñèå íà äîïðîñ ñ ïðèñòðàñòèåì.



    À çäåñü íàïîìíþ åù¸ îäèí ïðèìåð, ñ ãèðóäîòåðàïèåé. Ñïåöèàëüíî ïðèâîæó èìåííî å¸, ò.ê. ê ïèÿâêàì îòíîøåíèÿ íå èìåþ, è äàæå èõ ïîáàèâàþñü. Òàê ÷òî, íè êàêîé ëè÷íîé çàèíòåðåñîâàííîñòè. Ñêîëüêî âåêîâ ýòà òåðàïèÿ ïðàêòèêîâàëàñü? È êàêîå (â ëó÷øåì ñëó÷àå, èðîíè÷íîå) îòíîøåíèå äî ñàìîãî ïîñëåäíåãî âðåìåíè (ó ìíîãèõ è ñåé÷àñ) ê ãèðóäîòåðàïèè áûëî ó îôèöèàëüíîé ìåäèöèíû? È ÷òî ïîíàäîáèëîñü, ÷òîáû ñíà÷àëà â Åâðîïå, à çàòåì è FDA ýòó òåðàïèþ îôèöèàëüíî ïðèçíàëè? . http://forums./showpost.php?p=96654&postcount=5

  13. noonelive
    #58
    ×èòàòåëü Íåäóã.Ðó
    À çäåñü íàïîìíþ åù¸ îäèí ïðèìåð, ñ ãèðóäîòåðàïèåé. Ñïåöèàëüíî ïðèâîæó èìåííî å¸, ò.ê. ê ïèÿâêàì îòíîøåíèÿ íå èìåþ, è äàæå èõ ïîáàèâàþñü. Òàê ÷òî, íè êàêîé ëè÷íîé çàèíòåðåñîâàííîñòè. Ñêîëüêî âåêîâ ýòà òåðàïèÿ ïðàêòèêîâàëàñü? È êàêîå (â ëó÷øåì ñëó÷àå, èðîíè÷íîå) îòíîøåíèå äî ñàìîãî ïîñëåäíåãî âðåìåíè (ó ìíîãèõ è ñåé÷àñ) ê ãèðóäîòåðàïèè áûëî ó îôèöèàëüíîé ìåäèöèíû? È ÷òî ïîíàäîáèëîñü, ÷òîáû ñíà÷àëà â Åâðîïå, à çàòåì è FDA ýòó òåðàïèþ îôèöèàëüíî ïðèçíàëè?



    Íàïîìíèòå, ïîæàëóéñòà, åùå ïðî ïåíèöèëëèí. À ïîíàäîáèëèñü èì èññëåäîâàíèÿ GUSTO IIB, OASIS-2, HELVETICA è ìíîãèå äðóãèå. Êàê-òî íåóäîáíî íàïîìèíàòü, ÷òî ïèÿâêè íà ãðóäü è èíôóçèÿ ãèðóäèíà 3-5 äíåé 0,15 ìã/êã/÷ - ðàçíûå âåùè. Èëè íàäî áûëî äðóæíî âîçðàäîâàòüñÿ ñèíòåçó ãèðóäèíà è áèâàëèðóäèíà è ïîä ëîçóíãîì "íàðîäíîå - çíà÷èò îòëè÷íîå" ïóñòèòü â äåëî?

  14. Ìàðèê
    #59
    ×èòàòåëü Íåäóã.Ðó
    Çàéö …, èçâèíèòå, êðîëèê – ýòî íå òî..îëüêî öåííûé ìåõ.



    Dr, Âû ñîâåðøåííî ïðàâû, ìåæäó ÷èñòûì ãèðóäèíîì (èëè åãî àíàëîãàìè) è ïèÿâêàìè íåëüçÿ ñòàâèòü çíàê ðàâåíñòâà.  ñëþíå ïèÿâêè, êðîìå ãèðóäèíà, ñîäåðæàòñÿ íåñêîëüêî äåñÿòêîâ áèîëîãè÷åñêè àêòèâíûõ ñîåäèíåíèé. Òàê ÷òî, íà ÷òî ïîðîé ñïîñîáíà ïèÿâêà, ðåêîìáèíàíòíûé ãèðóäèí íå «ìîã¸ò».

  15. Ìàðèÿ Êîðîòêîâà
    #60
    ×èòàòåëü Íåäóã.Ðó
    Ìû îòîøëè îò òåìû. Ïîðà å¸ çàêðûòü.

Êëèíèêà ñòîìàòîëîãèè è êîñìåòîëîãèè â Ìîñêâå

Ìåòêè ýòîé òåìû

Âàøè ïðàâà

  • Âû ìîæåòå ñîçäàâàòü íîâûå òåìû
  • Âû ìîæåòå îòâå÷àòü â òåìàõ
  • Âû íå ìîæåòå ïðèêðåïëÿòü âëîæåíèÿ
  • Âû íå ìîæåòå ðåäàêòèðîâàòü ñâîè ñîîáùåíèÿ
  •